

**Baseline characteristics of European Union patients undergoing first myeloablative HCT for AML at age 15-39 years between 2000-2014 who survived disease free for 12+ months**

<b>Characteristic</b>	<b>All</b>	<b>Chemotherapy</b>	
	<b>Patients</b>	<b>TBI</b>	<b>only</b>
No. of patients	82	55	27
Graft type - no. (%)			
Bone marrow	27 (33)	18 (33)	9 (33)
Peripheral blood	55 (67)	37 (67)	18 (67)
Donor - no. (%)			
HLA-identical sibling	48 (59)	30 (55)	18 (67)
Matched (8/8) unrelated donor	34 (41)	25 (45)	9 (33)
Conditioning regimen - no. (%)			
TBI + cyclophosphamide	55 (67)	55	0
Busulfan + cyclophosphamide	27 (33)	0	27
ATG as conditioning regimen or GVHD prophylaxis - no. (%)			
No	66 (80)	46 (84)	20 (74)
Yes	16 (20)	9 (16)	7 (26)
Corticosteroids as part of GVHD prophylaxis - no. (%)			
No	78 (95)	53 (96)	25 (93)
Yes	4 (5)	2 (4)	2 (7)